The U.S. Food and Drug Administration has granted fast track status to FLX-787, Flex Pharma‘s treatment for severe muscle cramps in amyotrophic lateral sclerosis. Flex designed FLX-787 to interfere with transient receptor potential ion channels that are believed to play a role in nervous system pain and inflammation.
We know dealing with amyotrophic lateral sclerosis (ALS) sometimes feels like an uphill battle, both for the patients and the caregivers. You feel like you’re not doing enough or as if the disease is taking up all your time and attention. To help you on your journey, we’ve gathered a few quotes we thought…
Brainstorm Cell Therapeutics has received a $16 million grant from a state agency known as the California Institute for Regenerative Medicine to develop a Phase 3 clinical trial of its ALS stem-cell therapy NurOwn. NurOwn is based on mesenchymal stem cells, which can transform themselves into various types of cells. Brainstorm…
The Orlando-area medical marijuana company Green Relief is reminding Florida residents that the state no longer requires a 90-day waiting period before a patient with a serious disease like ALS can receive treatment. Florida lifted the 90-day requirement June 24 with rules that implemented changes in the state’s medical marijuana law…
Ipsen Biopharmaceuticals has entered an exclusive three-year agreement with Saol Therapeutics to promote Dysport (abobotulinumtoxinA), a therapy indicated for injection in adults with spasticity and in children with lower limb spasticity – common in amyotrophic lateral sclerosis (ALS) patients. Under the agreement, Saol will set up a…
Mitsubishi Tanabe Pharma America (MT Pharma America) has enrolled more than 700 sites of care in its newly created National Infusion Center Directory to help physicians identify local infusion centers for amyotrophic lateral sclerosis (ALS) patients who are prescribed Radicava (edaravone).
Measuring neurofilaments in brain and spinal fluid appears to be a reliable way of confirming an ALS diagnosis, Belgian and German researchers report. This finding is important because it takes an average of a year from the appearance of the first symptoms before doctors can diagnose the disease. The discovery could…
The Israel Innovation Authority (IIA) has awarded BrainStorm Cell Therapeutics a $2.1 million grant to support the development of NurOwn, an innovative mesenchymal stem cell-based platform to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).
The U.S. Food and Drug Administration has expanded its approval of Dysport (abobotulinumtoxinA) as a  treatment for spasticity in adults from not just the upper limbs but to the lower limbs as well, according to its maker, Ipsen Biopharmaceuticals. Spasticity can affect those with amyotrophic lateral sclerosis (ALS), multiple sclerosis, cerebral…
Flex Pharma, which develops therapies to reduce the cramps and shaking that are hallmarks of ALS and other neurological diseases, has a new CEO. Dr. William McVicar, head of the company’s research and development arm, will assume the interim chief executive’s post on July 3. He replaces Dr. Christoph Westphal, who…
Get regular updates to your inbox.